Global Familial Amyloid Polyneuropathy Market Size, Status and Forecast 2019-2025

Description

Familial amyloid polyneuropathy (FAP) or transthyretin (TTR) amyloid neuropathy are a rare group of autosomal dominant diseases caused by the deposition of protein and/or amyloid fibrils around the peripheral nerves and in various tissues, including the heart muscle.
Globally, development of new drugs for treatment of familial amyloid polyneuropathy, and rise in the prevalence of familial amyloid polyneuropathy are the prime growth drivers of familial amyloid polyneuropathy market.
In 2018, the global Familial Amyloid Polyneuropathy market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Familial Amyloid Polyneuropathy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Familial Amyloid Polyneuropathy development in United States, Europe and China.

The key players covered in this study
Pfizer
GSK
Ionis
Alnylam
Corino Therapeutics
Proclara Bioscience
Arcturus Therapeutics
...

Market segment by Type, the product can be split into
FAP-I
FAP-II
FAP-III
FAP-IV

Market segment by Application, split into
Hospitals and Clinics
Others

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Familial Amyloid Polyneuropathy status, future forecast, growth opportunity, key market and key players.
To present the Familial Amyloid Polyneuropathy development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Familial Amyloid Polyneuropathy are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

TABLE OF CONTENT

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Familial Amyloid Polyneuropathy Market Size Growth Rate by Type (2014-2025)
1.4.2 FAP-I
1.4.3 FAP-II
1.4.4 FAP-III
1.4.5 FAP-IV
1.5 Market by Application
1.5.1 Global Familial Amyloid Polyneuropathy Market Share by Application (2014-2025)
1.5.2 Hospitals and Clinics
1.5.3 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Familial Amyloid Polyneuropathy Market Size
2.2 Familial Amyloid Polyneuropathy Growth Trends by Regions
2.2.1 Familial Amyloid Polyneuropathy Market Size by Regions (2014-2025)
2.2.2 Familial Amyloid Polyneuropathy Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Familial Amyloid Polyneuropathy Market Size by Manufacturers
3.1.1 Global Familial Amyloid Polyneuropathy Revenue by Manufacturers (2014-2019)
3.1.2 Global Familial Amyloid Polyneuropathy Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Familial Amyloid Polyneuropathy Market Concentration Ratio (CR5 and HHI)
3.2 Familial Amyloid Polyneuropathy Key Players Head office and Area Served
3.3 Key Players Familial Amyloid Polyneuropathy Product/Solution/Service
3.4 Date of Enter into Familial Amyloid Polyneuropathy Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Familial Amyloid Polyneuropathy Market Size by Type (2014-2019)
4.2 Global Familial Amyloid Polyneuropathy Market Size by Application (2014-2019)

5 United States
5.1 United States Familial Amyloid Polyneuropathy Market Size (2014-2019)
5.2 Familial Amyloid Polyneuropathy Key Players in United States
5.3 United States Familial Amyloid Polyneuropathy Market Size by Type
5.4 United States Familial Amyloid Polyneuropathy Market Size by Application

6 Europe
6.1 Europe Familial Amyloid Polyneuropathy Market Size (2014-2019)
6.2 Familial Amyloid Polyneuropathy Key Players in Europe
6.3 Europe Familial Amyloid Polyneuropathy Market Size by Type
6.4 Europe Familial Amyloid Polyneuropathy Market Size by Application

7 China
7.1 China Familial Amyloid Polyneuropathy Market Size (2014-2019)
7.2 Familial Amyloid Polyneuropathy Key Players in China
7.3 China Familial Amyloid Polyneuropathy Market Size by Type
7.4 China Familial Amyloid Polyneuropathy Market Size by Application

8 Japan
8.1 Japan Familial Amyloid Polyneuropathy Market Size (2014-2019)
8.2 Familial Amyloid Polyneuropathy Key Players in Japan
8.3 Japan Familial Amyloid Polyneuropathy Market Size by Type
8.4 Japan Familial Amyloid Polyneuropathy Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Familial Amyloid Polyneuropathy Market Size (2014-2019)
9.2 Familial Amyloid Polyneuropathy Key Players in Southeast Asia
9.3 Southeast Asia Familial Amyloid Polyneuropathy Market Size by Type
9.4 Southeast Asia Familial Amyloid Polyneuropathy Market Size by Application

10 India
10.1 India Familial Amyloid Polyneuropathy Market Size (2014-2019)
10.2 Familial Amyloid Polyneuropathy Key Players in India
10.3 India Familial Amyloid Polyneuropathy Market Size by Type
10.4 India Familial Amyloid Polyneuropathy Market Size by Application

11 Central & South America
11.1 Central & South America Familial Amyloid Polyneuropathy Market Size (2014-2019)
11.2 Familial Amyloid Polyneuropathy Key Players in Central & South America
11.3 Central & South America Familial Amyloid Polyneuropathy Market Size by Type
11.4 Central & South America Familial Amyloid Polyneuropathy Market Size by Application

12 International Players Profiles
12.1 Pfizer
12.1.1 Pfizer Company Details
12.1.2 Company Description and Business Overview
12.1.3 Familial Amyloid Polyneuropathy Introduction
12.1.4 Pfizer Revenue in Familial Amyloid Polyneuropathy Business (2014-2019)
12.1.5 Pfizer Recent Development
12.2 GSK
12.2.1 GSK Company Details
12.2.2 Company Description and Business Overview
12.2.3 Familial Amyloid Polyneuropathy Introduction
12.2.4 GSK Revenue in Familial Amyloid Polyneuropathy Business (2014-2019)
12.2.5 GSK Recent Development
12.3 Ionis
12.3.1 Ionis Company Details
12.3.2 Company Description and Business Overview
12.3.3 Familial Amyloid Polyneuropathy Introduction
12.3.4 Ionis Revenue in Familial Amyloid Polyneuropathy Business (2014-2019)
12.3.5 Ionis Recent Development
12.4 Alnylam
12.4.1 Alnylam Company Details
12.4.2 Company Description and Business Overview
12.4.3 Familial Amyloid Polyneuropathy Introduction
12.4.4 Alnylam Revenue in Familial Amyloid Polyneuropathy Business (2014-2019)
12.4.5 Alnylam Recent Development
12.5 Corino Therapeutics
12.5.1 Corino Therapeutics Company Details
12.5.2 Company Description and Business Overview
12.5.3 Familial Amyloid Polyneuropathy Introduction
12.5.4 Corino Therapeutics Revenue in Familial Amyloid Polyneuropathy Business (2014-2019)
12.5.5 Corino Therapeutics Recent Development
12.6 Proclara Bioscience
12.6.1 Proclara Bioscience Company Details
12.6.2 Company Description and Business Overview
12.6.3 Familial Amyloid Polyneuropathy Introduction
12.6.4 Proclara Bioscience Revenue in Familial Amyloid Polyneuropathy Business (2014-2019)
12.6.5 Proclara Bioscience Recent Development
12.7 Arcturus Therapeutics
12.7.1 Arcturus Therapeutics Company Details
12.7.2 Company Description and Business Overview
12.7.3 Familial Amyloid Polyneuropathy Introduction
12.7.4 Arcturus Therapeutics Revenue in Familial Amyloid Polyneuropathy Business (2014-2019)
12.7.5 Arcturus Therapeutics Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details

Choose License Type

Checkout Inquiry Sample